AZD9550 + AZD6234 for Obesity
(ASCEND Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on a GLP1 medication, you must stop it at least 3 months before joining the trial.
How does the drug AZD9550 + AZD6234 for obesity differ from other treatments?
The drug AZD9550 + AZD6234 for obesity is unique because it combines two components, potentially offering a novel mechanism of action compared to existing treatments. While specific details about its mechanism are not provided, it may involve targeting multiple pathways, similar to other multireceptor agonists like LY3437943, which targets glucagon, GIP, and GLP-1 receptors to manage weight and improve metabolic health.12345
Eligibility Criteria
This trial is for individuals who are overweight or obese and have at least one weight-related health issue. Participants will receive weekly subcutaneous injections and must not be taking other weight loss medications.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive AZD9550 and AZD6234 in combination or as monotherapy for weight loss
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- AZD6234
- AZD9550
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from รcole nationale vรฉtรฉrinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from รcole nationale vรฉtรฉrinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology